ClinConnect ClinConnect Logo
Search / Trial NCT04679844

Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Autograft in Patients Undergoing Posterolateral Lumbar Fusion

Launched by KUROS BIOSURGERY AG · Dec 18, 2020

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

Degenerative Disc Disease Spine Fusion

ClinConnect Summary

This clinical trial is studying a product called MagnetOs Easypack Putty, which is a synthetic bone graft used during spine surgery for patients with back issues like degenerative disc disease. The goal is to see how effective this putty is when used alone, compared to other treatments that mix it with natural bone materials in patients undergoing spinal fusion surgery, specifically in the lower back.

To participate in this study, patients must be at least 18 years old and have specific spinal instability issues that require surgery. They should have tried other treatments for at least three months without success. Participants can expect to follow the study's procedures, which will help researchers learn more about the effectiveness of MagnetOs Easypack Putty. It's important to know that not everyone can join; for example, those who need more than two levels of fusion or have certain medical conditions may be excluded.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient is able to read/be read, understand, and provide written informed consent and has signed the Institutional Review Board (IRB) approved informed consent.
  • Male or female patient ≥ 18 years old.
  • Patients with segmental mechanical spinal instability requiring arthrodesis surgery.
  • Instability can be either caused by degenerative disc disease or by traumatic injury to the spinal column. Patient requiring a maximum of two-level instrumented posterolateral lumbar/thoraco-lumbar fusion (T11 - S1) will be enrolled. Mechanical instability is defined by the presence of one or more of the following:
  • 1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
  • 2. decreased disc height by \> 2 mm, but dependent upon the spinal level
  • 3. Grade II or more listhesis
  • 4. TLICS equal or greater than 5
  • 5. Unstable burst fracture
  • Failed conservative treatment (physical therapy, bed rest, medications, spinal injections, manipulations, or transcutaneous electrical nerve stimulation) for a minimum period of 3 months prior to study enrollment (if the patient undergoes elective surgery). Patients who have spinal instability (as defined above in inclusion criteria number three), caused by acute trauma requiring urgent surgical treatment are excluded from this criterion.
  • Exclusion Criteria:
  • Requires \> two-level fusion or expected to need secondary intervention within one year following surgery.
  • Had prior PLF fusion or attempted PLF fusion at the involved levels.
  • Had previous decompression at the involved levels.
  • Women who are or intend to become pregnant within the next 12 months.
  • To treat conditions in which general bone grafting is not advisable.
  • In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilization is not possible).
  • In case of significant vascular impairment proximal to the graft site.
  • In case of severe metabolic or systemic bone disorders (e.g., osteogenesis imperfecta, history of or active Pott's disease, stage \>4 renal disease or Paget's Disease) that affect bone or wound healing.
  • In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
  • When intraoperative soft tissue coverage is not planned or possible.
  • Receiving treatment with medication interfering with calcium metabolism.
  • Has degenerative disc disease (DDD) related to a benign or malignant tumor.
  • Has history or presence of active malignancy.
  • Has known substance abuse, psychiatric disorder, or a condition which, in the opinion of the investigator, may influence the healing or ability to comply with protocol requirements.
  • Is involved in active litigation relating to his/her spinal condition.
  • Has participated in an investigational study within 30 days prior to surgery for study devices.

About Kuros Biosurgery Ag

Kuros Biosurgery AG is a leading biotechnology company focused on developing innovative therapeutic solutions for tissue regeneration and wound healing. Leveraging advanced biomaterial technologies, the company specializes in the creation of novel surgical products designed to enhance healing processes and improve patient outcomes across a range of surgical applications. With a commitment to scientific excellence and rigorous clinical development, Kuros Biosurgery AG aims to address unmet medical needs by providing healthcare professionals with effective tools that promote safe and efficient surgical interventions.

Locations

Seattle, Washington, United States

Nashville, Tennessee, United States

Detroit, Michigan, United States

Pennington, New Jersey, United States

Patients applied

0 patients applied

Trial Officials

Katherine Sage, DO

Study Director

Kuros BioSciences B.V.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials